SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.

EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

Discount Code

I want to receive updates from celltelligence.com.

By selecting this, I agree to receive emails from celltelligence.com.

Processing...

Already have an account? Log in here

RETURN TO HOME

Autologous, CAR-T, CD19

December 17, 2021

Daiichi Sankyo Authorizes Yescarta’s First Treatment Center in Japan 11 Months After Approval

Here is a brief preview of this blast: On Thursday, December 16, Gilead (Kite) announced (press release) that Daiichi Sankyo has authorized Yescarta’s (Gilead’s CD19 CAR-T) first treatment center in Japan. Below, Celltelligence provides insights on how Yescarta’s footprint in Japan may potentially increase Gilead’s (Kite) WW market revenue, while discussing differences in ATC onboarding rates between the US and Japan.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.